Halle Berry Women's HRT: Hypothesized Full Protocol

What Halle Berry Has Actually Said About HRT

Halle Berry has been one of the most visible public advocates for menopause literacy in the United States. She has not released her medical records, but her statements across interviews, social media, and congressional testimony provide a traceable account of what she uses and why.

Her Diagnosis Story

Berry has recounted publicly that she first experienced perimenopausal symptoms in her late 20s. Her physicians initially misdiagnosed her with a sexually transmitted infection rather than recognizing perimenopause, a diagnostic error that is well-documented in the literature: the average time from symptom onset to menopause diagnosis in women under 45 runs 4 to 6 years according to data from the SWAN (Study of Women's Health Across the Nation) cohort [1].

That delay shaped her advocacy. In 2023 she testified before the U.S. Senate Aging Committee to push for expanded menopause research funding, stating (direct quote): "I was told I had herpes, and I did not. I was in perimenopause."

Pellet Therapy Confirmation

In a 2023 Instagram post and in her interview on "The Checkup with Doctor David Agus" (CBS News), Berry explicitly mentioned pellet-based hormone therapy as her delivery method. She described the insertion procedure, the testosterone component, and the freedom from daily dosing as reasons she prefers the format. This is confirmed, not inferred.

She also stated she works closely with a physician to monitor her levels, consistent with standard pellet-therapy management protocols.

The Pharmacology of Pellet Therapy

Pellets are compressed cylinders of crystalline hormone, typically 3 to 9 mm in diameter, inserted subcutaneously in the upper outer buttock under local anesthesia. They are not FDA-approved as finished drug products [2], yet they are widely compounded under 503A and 503B pharmacy designations [3].

Estradiol Pellets

Estradiol pellets release hormone continuously by passive diffusion. Typical female insertion doses range from 25 mg to 150 mg, with re-insertion every 3 to 6 months depending on symptom recurrence and serum estradiol trough levels. Target serum estradiol for symptom relief generally runs 40 to 200 pg/mL per clinical practice guidance, though The Menopause Society notes there is no universally established target range for pellet delivery specifically [4].

A 2020 observational study (N=837) published in Maturitas found that subcutaneous estradiol pellets maintained mean serum estradiol of 122 pg/mL at 90 days post-insertion [5]. Symptom scores (Greene Climacteric Scale) improved by 68% from baseline, though the study lacked a placebo arm, limiting causal interpretation.

Testosterone Pellets in Women

Berry has explicitly confirmed testosterone use. This is among the most clinically active areas of women's HRT research. The Global Consensus Position Statement on Testosterone Therapy for Women (2019), co-authored by The Menopause Society, the British Menopause Society, and the International Menopause Society, supports testosterone use for hypoactive sexual desire disorder (HSDD) in postmenopausal women, with a target serum testosterone in the premenopausal female physiological range (15 to 70 ng/dL) [6].

Female testosterone pellet doses typically deliver 2 to 10 mg per day equivalent; common pellet sizes run 12.5 mg to 75 mg total with 3-to-4-month resorption cycles. Supraphysiologic dosing above 150 ng/dL serum testosterone carries risk of acne, androgenic alopecia, and clitoromegaly, which is why regular monitoring every 4 to 6 weeks post-insertion is standard practice [6].

Progesterone: The Missing Piece (Inference)

Berry has not publicly confirmed progesterone use. This section is clearly labeled as clinical inference.

Any woman with an intact uterus receiving systemic estradiol requires endometrial protection via a progestogen. Without it, unopposed estrogen raises endometrial cancer risk 2- to 12-fold depending on duration and dose [7]. The most evidence-supported option for women using bioidentical protocols is oral micronized progesterone (OMP, brand name Prometrium) 200 mg nightly for 12 days per cycle or 100 mg nightly continuously.

The KEEPS trial (Kronos Early Estrogen Prevention Study, N=727) compared oral conjugated equine estrogen plus OMP vs. Transdermal estradiol plus OMP vs. Placebo and found OMP produced less breast tenderness and fewer mood side effects than synthetic progestins [8]. For women who prefer to avoid daily oral dosing, progesterone can also be compounded into a sustained-release vaginal suppository or a topical cream, though systemic absorption of topical cream progesterone remains unreliable [9].

Given Berry's stated preference for pellet-based delivery and minimal daily burden, she may use an oral micronized progesterone taken nightly, or a compounded sustained-release progesterone pellet. The latter is not well-studied and not formally recommended by The Menopause Society [4].

Estradiol Delivery: Why Pellets vs. Patches vs. Pills Matter

The delivery route for estradiol changes its metabolic footprint substantially. Oral estrogens undergo first-pass hepatic metabolism, raising sex hormone-binding globulin (SHBG), C-reactive protein, and triglycerides compared with transdermal routes [10]. Transdermal and pellet routes bypass the liver and produce more stable serum levels, which may explain a more favorable venous thromboembolism (VTE) profile.

VTE Risk by Route

The ESTHER study (N=881 cases, 1,452 controls) found that oral estrogen users had a 4-fold higher VTE risk compared to non-users, while transdermal estrogen users showed no statistically significant increase (OR 0.9, 95% CI 0.5 to 1.6) [11]. Pellets, delivering estradiol transdermally via the subcutaneous route, are presumed to carry a similar low VTE risk profile, though pellet-specific VTE data from randomized controlled trials do not yet exist [4].

Breast Cancer Context

The Women's Health Initiative (WHI) original 2002 publication linked combined estrogen-progestin therapy to increased breast cancer incidence (HR 1.26, 95% CI 1.00 to 1.59) [12]. However, the WHI used conjugated equine estrogen plus medroxyprogesterone acetate, not bioidentical estradiol plus micronized progesterone. The E3N cohort (N=80,377 French women) found that estradiol combined with OMP carried no significant increase in breast cancer risk over 8.1 years of follow-up (RR 1.00, 95% CI 0.83 to 1.22) [13].

Berry has not addressed breast cancer risk publicly in the context of her HRT use.

Hypothesized Full Protocol: Annotated Summary

This section synthesizes Berry's confirmed statements with clinical inference to sketch what a protocol under her described parameters would likely include. Every element is labeled.

Agent 1: Estradiol pellet

• Status: CONFIRMED (delivery method confirmed; dose inferred)
• Likely dose: 75 to 100 mg subcutaneous pellet, re-inserted every 3 to 4 months
• Target serum level: 80 to 150 pg/mL trough
• Monitoring: Serum estradiol 4 weeks post-insertion, then at trough before re-insertion

Agent 2: Testosterone pellet or cream

• Status: CONFIRMED (use confirmed; form and dose inferred)
• Likely pellet dose: 25 to 50 mg per insertion (delivers approximately 3 to 6 mg/day)
• Target serum level: 15 to 70 ng/dL (premenopausal physiological range) [6]
• Monitoring: Total testosterone and free testosterone at 4 to 6 weeks post-insertion

Agent 3: Micronized progesterone

• Status: INFERRED (required for uterine protection; Berry has not confirmed)
• Likely dose: 100 to 200 mg oral nightly (continuous) or compounded sustained-release
• Rationale: Endometrial protection for any intact-uterus estrogen user [7]
• Monitoring: Annual endometrial ultrasound if symptomatic bleeding occurs

Agent 4: DHEA (Dehydroepiandrosterone)

• Status: SPECULATIVE (commonly co-prescribed in pellet protocols; no public confirmation)
• Typical dose: 25 to 50 mg/day oral or compounded pellet
• Role: Adrenal androgen precursor; may support libido and energy independent of direct testosterone [14]

Agent 5: Vaginal estrogen

• Status: SPECULATIVE (commonly added for genitourinary syndrome; not confirmed)
• Typical dose: Estradiol cream 0.5 g (0.1 mg estradiol) 2 to 3 times weekly or Ospemifene 60 mg daily
• Systemic absorption from low-dose vaginal estradiol is negligible and considered safe even in breast cancer survivors per ACOG guidelines [15]

The Clinical Evidence Behind Pellet Therapy: Where It Stands

Pellet therapy occupies an unusual position: widely practiced, strongly advocated by a vocal community of prescribers, and simultaneously under-studied in large randomized controlled trials.

What the Evidence Supports

A 2018 systematic review in Postgraduate Medicine (N=13 studies) found consistent improvements in vasomotor symptoms, libido, and bone density with pellet estradiol, but noted that all included studies were observational, with sample sizes under 1,000 [16]. No head-to-head trial has compared pellets to FDA-approved transdermal patches for symptom control or safety outcomes.

The Menopause Society's 2022 position statement states: "Hormone therapy remains the most effective treatment for vasomotor symptoms and is approved for the prevention of osteoporosis; for women who are within 10 years of menopause or aged <60 years, the benefits generally outweigh the risks." [4] That endorsement applies to FDA-approved formulations; the Society does not formally endorse compounded pellets due to the absence of standardized dosing data.

Dosing Variability Risk

Because pellets are compounded rather than manufactured under FDA finished-drug standards, potency can vary by 10 to 20% between batches [3]. This variability creates risk of supraphysiologic peaks immediately after insertion, particularly for testosterone in women. Supraphysiologic testosterone (>150 ng/dL) in women has been associated with polycythemia, lipid changes, and androgenic side effects [6].

Monitoring Schedule Recommended

A reasonable monitoring schedule for a pellet-based female HRT protocol includes:

• Baseline labs before first insertion: Estradiol, total and free testosterone, SHBG, complete blood count, lipid panel, TSH
• 4 to 6 weeks post-insertion: Estradiol, total testosterone, free testosterone
• Before each re-insertion: Same panel plus symptom review
• Annually: Mammogram per screening guidelines [17], endometrial ultrasound if breakthrough bleeding occurs, bone density DEXA if age-appropriate [18]

Menopause Advocacy: Berry's Policy and Public Health Role

Berry's public platform extends beyond personal disclosure. Her 2023 Senate testimony and the launch of Respin (a menopause education nonprofit) have brought clinical attention to gaps in U.S. Menopause care.

The data behind those gaps are striking. A 2022 survey published in Menopause (N=1,000 OB-GYN residents) found that only 31% felt adequately trained to manage menopausal symptoms [19]. The same year, a Mayo Clinic study estimated that menopause-related lost productivity costs U.S. Employers approximately $1.8 billion annually [20].

Berry's advocacy aligns with the American College of Obstetricians and Gynecologists' call in Practice Bulletin 141 for routine menopause counseling at annual well-woman visits, which notes: "Clinicians should be prepared to discuss the benefits and risks of hormone therapy with symptomatic patients." [15]

The Misdiagnosis Problem

The error Berry described, being told perimenopause symptoms were an STI, is not isolated. Perimenopause in women under 40 (premature ovarian insufficiency, or POI) affects approximately 1% of women and is frequently missed [21]. The SWAN study found that Black women experience more severe vasomotor symptoms and earlier onset compared to white women, yet receive HRT at lower rates [1]. Berry's experience tracks closely with these documented disparities.

What Respin Is Trying to Change

Respin's stated mission includes pushing for menopause to be included in medical school curricula, increasing NIH funding for menopausal research (currently under 2% of total NIH funding according to advocacy group estimates), and reducing the stigma that causes women to underreport symptoms to their physicians.

Safety Monitoring and When HRT Is Not Appropriate

Not every woman is a candidate for systemic HRT. Absolute contraindications include unexplained vaginal bleeding, active or recent (within 12 months) breast cancer, active VTE or arterial thromboembolism, known thrombophilic disorder, active liver disease, and estrogen-sensitive gynecologic cancers [4].

Women over age 60 initiating HRT for the first time face a less favorable benefit-to-risk ratio. The WHI re-analysis (2017) confirmed that women who began estrogen therapy within 10 years of menopause or before age 60 had a 23% reduction in all-cause mortality compared to placebo (HR 0.77, 95% CI 0.69 to 0.87) [22]. Women who started 20 or more years post-menopause showed no mortality benefit.

A CBC is warranted every 6 months for women on testosterone pellets given the rare risk of polycythemia. Hematocrit above 50% warrants dose reduction or temporary suspension of testosterone [6].

How This Protocol Compares to FDA-Approved Options

Berry's apparent preference for compounded pellets places her outside the standard FDA-approved HRT armamentarium, but the underlying hormones are the same molecules used in approved products.

FDA-approved options that cover similar therapeutic goals include:

• Estradiol transdermal patch (Climara, Vivelle-Dot): 0.025 to 0.1 mg/day, changed weekly or twice weekly [2]
• Oral estradiol (Estrace): 0.5 to 2 mg/day
• Testosterone (no FDA-approved product exists for women in the U.S.; off-label use of male products at 1/10th dose is common) [6]
• Micronized progesterone (Prometrium): 100 to 200 mg/day oral [8]

The practical difference between a pellet protocol and patch-plus-pill is largely one of dosing frequency and serum level stability, not molecular identity. Pellets trade FDA oversight and standardized dosing for convenience and steady-state delivery.